.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AD01_Carmustine.Carmustine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AD01_Carmustine.Carmustine| name: | Carmustine |
| ATC code: | L01AD01 | route: | intravenous |
| n-compartments | 2 |
Carmustine (BCNU) is a nitrosourea alkylating agent used as an antineoplastic (anticancer) drug, mainly for the treatment of brain tumors, multiple myeloma, and lymphomas. It is cytotoxic and works by cross-linking DNA and RNA, thereby inhibiting DNA replication and transcription. Carmustine is approved and still used clinically, particularly for brain tumors due to its ability to cross the blood-brain barrier.
Pharmacokinetics in adult cancer patients, typical dosing regimen; parameters for intravenous administration.
Tran, L, et al., & Huitema, AD (2010). Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Human antibodies 19(1) 7–13. DOI:10.3233/HAB-2010-0215 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20555126
Jackson, NC, et al., & Sharma, HL (1992). Cell-targeted 114Inm and drug (BCNU) combination therapy in a rat acute lymphoblastic leukaemia. Nuclear medicine communications 13(8) 614–619. PUBMED:https://pubmed.ncbi.nlm.nih.gov/1513524